The growth of this market can be attributed to the rising preference for continuous manufacturing in the biopharmaceutical industry and the increasing demand for biopharmaceuticals across the globe.The Hollow Fiber Filtration Market is projected to reach USD 517.4 million by 2023 from USD 274.7 million in 2018, growing at a CAGR of 13.5%.

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267011039On the basis of application, the hollow fiber filtration market is segmented into continuous cell perfusion, harvest and clarification, and concentration and diafiltration.

In 2018, continuous cell perfusion is expected to be the largest application segment in the hollow fiber filtration market.

The biopharmaceutical industry is actively exploring the potential of continuous manufacturing, with a focus on upstream perfusion cell-culture processes that utilize hollow fiber filters.

On the basis of material, the hollow fiber filtration market is segmented into polymeric and ceramic materials.

In 2018, the polymeric hollow fiber filtration segment is expected to account for a larger share of the market as these filters are widely used in several ultrafiltration and microfiltration applications, including filtration, desalination, and biochemical reactions.The Asian Pacific is expected to be the fastest-growing regional market for hollow fiber filtration.

Increasing number of personalized medicines targeting a specific population coupled with rising number of FDA approved orphan drugs has increased bioproduction, accelerating the bioreactors demand over the forecast years.Request for a sample of this report @ https://www.graphicalresearch.com/request/1222/sampleAccording to the Graphical Research new growth forecast report titled North America Bioreactors Market By Technology (Wave-induced Motion SUB, Stirred SUB, Single Use Bubble Column), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By End-use (R Organizations, Biopharma Manufacturers, CMOs), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells) estimated to exceed USD 790 million by 2025.North America Bioreactors Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:North America Bioreactors Market Value, By Cell, 2014-2025, (USD Million)Mammalian cellsBacterial cellsYeast cellsNorth America Bioreactors Market Size, By Molecule, 2014-2025, (USD Million)Monoclonal antibodiesVaccinesRecombinant proteinStem cellGene therapyOthersMake an Inquiry for purchasing this Report @ https://www.graphicalresearch.com/request/1222/inquiry-before-buyingNorth America Bioreactors Market Share, By Technology, 2014-2025, (USD Million)Wave-induced motion SUBStirred SUBStirred-use bubble columnOthersNorth America Bioreactors Market Forecast, By End-use, 2014-2025, (USD Million)Research and development (R) organizationsBiopharma manufacturersContract manufacturing organizations (CMOs)Rising prevalence of chronic diseases, and growing biopharmaceutical investments will drive the global bioreactors market size.

Moreover, various advancements in tank design to meet the growing needs of biopharmaceutical industry will be conducive to the market growth.However, regulatory concerns regarding single-use bioreactor, vulnerability to leaching, and limited storage capacity should hinder bioreactor market growth.

Additionally, large-scale disposal of plastic derivatives is a growing environmental concern restraining the business growth over the forecast years.Mammalian cells segment is estimated to expand at 17.9% CAGR over the forecast timeframe, owing to its wide application in production of viral vaccines and therapeutic proteins.

Additionally, emergence of gene therapy and tissue engineering coupled with demand for smart and regenerative medicine should boost the industry growth over the forecast years.Browse Table of Contents @ https://www.graphicalresearch.com/table-of-content/1222/north-america-bioreactors-marketMonoclonal antibodies (mAb) generated over USD 100 million in 2018 owing to its increasing application in treatment of breast cancers, asthma, rheumatoid arthritis, leukemia, psoriasis chronic gastrointestinal inflammatory disease, and transplant rejection.

It is mainly used in laboratory and pilot plant scale-up owing to better flexibility with adequate productivity.

High growth is attributed to increase in number of biopharmaceutical products in pipeline including antibodies and antibody drug conjugates coupled with rising number of new facilities to meet the production needs.

The Global Bioproduction Cmo & Cro Market Report, with its in-depth industry analysis of the market, estimates the industry size bifurcated into segments and regions.

The Market report covers the regional, global and country level analysis with an exhaustive insight of the overall development prospects in the market.

Besides, it sheds light on comprehensive competitive landscape of global market.

The study supplementary offers dashboard outline of the major players encompassing their fruitful marketing plans, recent developments, market contribution etc.

in both historic and the present contexts.Why Bioproduction Cmo & Cro Report is Important to You:Bioproduction Cmo & Cro Market Research Report includes various topics that will brief you about total industry Size, Key Market Drivers, Challenges, Growth Opportunities, Industry Share, Growth, Demand, Outlook etc.

Furthermore, it covers Covid-19 Impact , key market updates, the impact of regulations and technological updates in.

WhiteLab Genomics, specialist in artificial intelligence (AI) dedicated to gene and cell therapies, is entering into a collaboration with ART-TG, Inserm laboratory expert in the preclinical and pharmaceutical development of ex vivo gene therapies.The two players are joining forces to improve the processes for the bioproduction of lentiviral gene therapy vectors using artificial intelligence.As part of this partnership, the teams from the Accelerator for technological research in genomic therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors and which will be used to identify the parameters allowing significant increase in the quality of the vectors as well as their production yields, and to reduce the production costs.Cell and gene therapy represents a new biomedical approach, in full economic expansion and with the potential to treat a growing number of genetic and acquired diseases such as cancers.

The pharmaceutical manufacture of these Advanced Medicinal Therapies requires acceleration in terms of standardization and process control to respond to their growth.

The collaboration is focused on the production of lentiviral vectors, which are used in various gene therapy approaches including for the manufacture of CAR-T cells, because purifying lentiviral vectors remains complex and is at critical capacity.

The teams will use AI to analyze multiple sources of information in order to optimize existing processes and to develop innovative processes.

The approach carried out with the lentiviral vectors here, will be applicable to other bioproducts.This project is made possible by funding from the Ile de France Region, which supports Bioproduction efforts as part of its Ile-de-France Leader Bioproduction scheme launched at the end of 2020.What do the experts say?“This collaboration with WhiteLab Genomics will allow us to integrate a large body of information on critical parameters and their interconnections in complex processes so that we can very rapidly adapt our experiments; a new way for us to work, to accelerate our strategic projects and to innovate ”, estimates Dr. Anne Galy, director of ART-TG.“The collaboration with ART-TG allows us to work with global experts in the field of lentiviral vector bioproduction,” said David Del Bourgo, CEO and co-founder of WhiteLab Genomics.

The work that will be carried out during this joint project will make it possible to find innovative solutions on the methods of capture and purification of vectors and to increase their yields significantly.